Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05459753 · ClinicalTrials.gov registry record · NA
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
A NA study of Parkinson Disease and Progressive Supranuclear Palsy, sponsored by University of Michigan.
- Active
- Registry status
- NA
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT05459753: Active NA study of Parkinson Disease and Progressive Supranuclear Palsy, sponsored by University of Michigan.
NCT05459753 is a NA study of Parkinson Disease and Progressive Supranuclear Palsy that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 125 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05459753, a NA study of Parkinson Disease and Progressive Supranuclear Palsy, is active but no longer recruiting, sponsored by University of Michigan.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
To perform a prospective cohort study with \[(18)F\]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year follow-up in PD subjects at risk of conversion to non-episodic and episodic (falls and FoG) PIGD motor features and cognitive changes at the same time points.
Primary Outcome
Interval change baseline vs 2-yr follow-up on the UPDRS motor score. UPDRS motor section is scored from 0-132, with higher scores indicating more severe motor symptoms.
Conditions Studied
Interventions
- RADIATION (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET
- RADIATION Dihydrotetrabenazine (DTBZ) PET
Study Locations (1)
Michigan
- University of Michigan - Michigan Medicine - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT05459753 still lists
NCT05459753 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET is the first listed.
NCT05459753 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05459753 about?
NCT05459753 is a clinical study titled "Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)". To perform a prospective cohort study with \[(18)F\]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year follow-up in PD subjects at risk of conversion to non-episodic and episodic (falls and FoG) PIGD motor features and cognitive changes at the same time points.
What is the current status of trial NCT05459753?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2022-03-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05459753 study?
This clinical trial studies the following conditions: Parkinson Disease, Progressive Supranuclear Palsy.
What interventions are being tested in trial NCT05459753?
The interventions under investigation include: (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET (RADIATION), Dihydrotetrabenazine (DTBZ) PET (RADIATION).
Who is sponsoring clinical trial NCT05459753?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05459753 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05459753's enrollment target sits among peer trials
125 68th of 297 higher than 230 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI